MCKNYSE—64

MCKESSON CORP

PharmaceuticalsVerified

MCKESSON CORP (MCK) is currently classified as Pharmaceuticals & Medical Research within Pharmaceuticals (Healthcare). Classification confidence: 0.92 (verified market data). Capital structure on the latest snapshot: total assets 84,190,000,000 USD, total equity -1,298,000,000, short-term debt 0, long-term debt 5,425,000,000. Net cash position is approximately -2,466,000,000 USD. Profitability profile: revenue 307,135,000,000, gross profit 10,506,000,000, operating income 4,062,000,000, net income 3,080,000,000. Return on equity ~-237.3%. Return on assets ~3.7%. Operating-cash-flow to net-income ratio is 0.89. Risk profile from automated assessment: liquidity risk high, dilution risk medium. Flags: Current liabilities exceed current assets.; Net cash is negative after subtracting total debt.; Source documents mention dilution or offering risk..

30-day price · MCK-111.24 (-12.5%)

Low$723.68High$892.22Close$775.97As of18 May, 00:00 UTC

Profile

CompanyMCKESSON CORP

ExchangeNYSE

TickerMCK

CIK0000927653

SICWholesale-Drugs, Proprietaries & Druggists' Sundries

SectorHealthcare

BusinessPharmaceuticals & Medical Research

Industry groupPharmaceuticals & Medical Research

IndustryPharmaceuticals

AI analysis

Business. MCKESSON CORP is classified under Healthcare / Pharmaceuticals and appears profitable on the latest normalized snapshot.

Classification. Classification confidence is 0.92 based on verified market data; matched terms: Pharmaceuticals, Pharmaceuticals & Medical Research, Healthcare.

Key takeaways

Return on equity is about -237.3%.
Debt to equity is about -4.18x.

Financial snapshot

PeriodQ3 2026

CurrencyUSD

Revenue$307.13B

Gross profit$10.51B

Operating income$4.06B

Net income$3.08B

R&D—

SG&A—

D&A—

SBC—

Operating cash flow$2.73B

CapEx$325.0M

Free cash flow$2.41B

Total assets$84.19B

Total liabilities—

Total equity-$1.30B

Cash & equivalents$2.96B

Long-term debt$5.42B

Annual history (last 5)

PeriodRevenueOp IncomeNet IncomeFCF

FY2025$359.05B$4.42B$3.29B$5.55B

FY2024$308.95B$3.91B$3.00B$3.88B

FY2025$308.95B$3.91B$3.00B$3.88B

FY2023$276.71B$4.38B$3.56B$4.77B

FY2024$276.71B$4.38B$3.56B$4.77B

PeriodGross %Op %Net %FCF %

FY2025————

FY2024————

FY2025————

FY2023————

FY2024————

PeriodAssetsEquityCashDebt

FY2025$75.14B-$2.07B$5.69B—

FY2024$67.44B-$1.97B$4.58B—

FY2025$67.44B-$1.97B$4.58B—

FY2023$62.32B-$1.86B$4.68B—

FY2024$62.32B-$1.86B$4.68B—

PeriodOCFCapExFCFSBC

FY2025$6.08B$537.0M$5.55B$226.0M

FY2024$4.31B$431.0M$3.88B$182.0M

FY2025$4.31B$431.0M$3.88B$182.0M

FY2023$5.16B$390.0M$4.77B$162.0M

FY2024$5.16B$390.0M$4.77B$162.0M

Quarterly history (last 4)

PeriodRevenueOp IncomeNet IncomeFCF

Q3 2026$307.13B$4.06B$3.08B$2.41B

Q2 2026$200.98B$2.44B$1.89B$1.28B

Q3 2026————

Q1 2026$97.83B$1.04B$784.0M-$1.03B

PeriodGross %Op %Net %FCF %

Q3 2026————

Q2 2026————

Q3 2026————

Q1 2026————

PeriodAssetsEquityCashDebt

Q3 2026$84.19B-$1.30B$2.96B—

Q2 2026$84.16B-$1.74B$4.00B—

Q3 2026—-$1.35B——

Q1 2026$81.31B-$1.97B$2.42B—

PeriodOCFCapExFCFSBC

Q3 2026$2.73B$325.0M$2.41B—

Q2 2026$1.50B$217.0M$1.28B—

Q3 2026————

Q1 2026-$918.0M$111.0M-$1.03B—

Valuation

Market price—

Market cap—

Enterprise value—

P/E—

Reported non-GAAP P/E—

EV/Revenue—

EV/Op income—

EV/OCF—

P/B—

P/Tangible book—

Tangible book—

Net cash-$2.47B

Current ratio0.9

Debt/Equity-4.2

ROA3.7%

ROE-2.4%

Cash conversion89.0%

CapEx/Revenue0.1%

SBC/Revenue—

Asset intensity0.0

Dilution ratio—

Risk assessment

Dilution riskMedium

Liquidity riskHigh

Current liabilities exceed current assets.
Net cash is negative after subtracting total debt.
Source documents mention dilution or offering risk.

Industry benchmarks

Activity: Pharmaceuticals & Medical Research · cohort 1 companies

MetricMCKActivity

Op margin1.3%-2.9% medp25 -218.9% · p75 9.6%above median

Net margin1.0%28.2% medp25 28.2% · p75 28.2%bottom quartile

Gross margin3.4%47.8% medp25 27.6% · p75 68.9%bottom quartile

CapEx / revenue0.1%6.6% medp25 6.6% · p75 6.6%bottom quartile

Debt / equity-418.0%271.5% medp25 271.5% · p75 271.5%bottom quartile

Observations

IR observations

Mean price target981.56 USD

Median price target975.00 USD

High price target1,085.00 USD

Low price target867.33 USD

Mean recommendation1.74 (1=strong buy, 5=strong sell)

Strong-buy count7.00

Buy count10.00

Hold count2.00

Sell count0.00

Strong-sell count0.00

Mean EPS estimate38.99 USD

Last actual EPS33.05 USD

Source data

Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.

SEC filingstype companyfacts · CIK 0000927653 · 689 us-gaap concepts

data.sec.gov/CIK0000927653.json

2026-05-01 03:33 UTC#c19aa938

Source: analysis-pipeline (hybrid)Generated: 2026-05-01 03:34 UTCJob: 33e59da3